ArticleJournal of medical Internet research2019
Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.
Article in Journal of medical Internet research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02943538 (Clinical Impact of Telemedicine in Crohn's Disease and Ulcerative Colitis), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Impact of Telemedicine in Crohn's Disease and Ulcerative Colitis: Study Teccu
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evidence for the Use of Patient-Reported Outcome Measures in the Treatment of Patients With Noncommunicable Diseases: Systematic Review.JMIR medical informatics · 2025Pooled it
- Remote care through telehealth for people with inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Pooled it
- The cost-effectiveness of digital health interventions: A systematic review of the literature.Frontiers in public health · 2022Pooled it
- Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU.Journal of medical Internet research · 2024Trial
- Identifying and Comparing Intervention Cost Components in Remote Patient Monitoring: A Scoping Review.PharmacoEconomics · 2026Article
- The impact of nurse-led care in inflammatory bowel disease management: a systematic review.BMC nursing · 2026Article
- Investigation of Appropriate Telemedicine for Patients with Inflammatory Bowel Disease.Internal medicine (Tokyo, Japan) · 2026Article
- Implementation of values-based healthcare in inflammatory bowel disease-a review.Journal of Crohn's & colitis · 2026Review
- The Impact of Proactive Fecal Calprotectin Collection in an Outreach Protocol for Biologic-Naïve Ulcerative Colitis Patients-Ulcerative Colitis Clinical Outreach (UCCO).Diseases (Basel, Switzerland) · 2025Article
- The Costs of Home Monitoring by Telemedicine vs Standard Care for Inflammatory Bowel Diseases-A Danish Register-Based, 5-Year Follow-up Study.Journal of Crohn's & colitis · 2025Article
- Development and validation of a scale to measure the care needs of Crohn's disease patients: a mixed-methods study.BMC nursing · 2024Article
- Economic evaluation of remote patient monitoring and organizational analysis according to patient involvement: a scoping review.International journal of technology assessment in health care · 2023Article
- Telemedicine in inflammatory bowel diseases: A new brick in the medicine of the future?World journal of methodology · 2023Review
- Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers.World journal of gastroenterology · 2023Review
- Editorial: the impact of COVID on the management of IBD flares: different care but similar outcomes-authors' reply.Alimentary pharmacology & therapeutics · 2023Article
- Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?Gastroenterologia y hepatologia · 2022Observational
- Telemonitoring for patients with inflammatory bowel disease amid the COVID-19 pandemic-A cost-effectiveness analysis.PloS one · 2022Article
- Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.Journal of medical Internet research · 2021Article
- COVID-19 quarantine measures are associated with negative social impacts and compromised follow-up care in patients with inflammatory bowel disease in Brazil.Annals of gastroenterology · 2021Article
- Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?Gastroenterologia y hepatologia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough electronic health interventions are considered safe and efficient, evidence regarding the cost-effectiveness of telemonitoring in inflammatory bowel disease is lacking.
objectiveWe aimed to evaluate the cost-effectiveness and cost-utility of the Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn's Disease and Ulcerative Colitis [TECCU]) Web platform (G_TECCU intervention group) for telemonitoring complex inflammatory bowel disease, compared with standard care (G_control) and nurse-assisted telephone care (G_NT intervention group).
methodsWe analyzed cost-effectiveness from a societal perspective by comparing the 3 follow-up methods used in a previous 24-week randomized controlled trial, conducted at a tertiary university hospital in Spain. Patients with inflammatory bowel disease who initiated immunosuppressants or biologic agents, or both, to control inflammatory activity were recruited consecutively. Data on the effects on disease activity (using clinical indexes) and quality-adjusted life-years (using the EuroQol 5 dimensions questionnaire) were collected. We calculated the costs of health care, equipment, and patients' productivity and social activity impairment. We compared the mean costs per patient, utilities, and bootstrapped differences.
resultsWe included 63 patients (21 patients per group). TECCU saved €1005 (US $1100) per additional patient in remission compared with G_control (95% CI €-13,518 to 3137; US $-14,798 to 3434), with a 79.96% probability of being more effective at lower costs. Compared with G_NT, TECCU saved €2250 (US $2463) per additional patient in remission (95% CI €-15,363 to 11,086; US $-16,817 to 12,135), and G_NT saved €538 (US $589) compared with G_control (95% CI €-6475 to 5303; US $-7088 to 5805). G_TECCU and G_NT showed an 84% and 67% probability, respectively, of producing a cost saving per additional quality-adjusted life-year (QALY) compared with G_control, considering those simulations that involved negative incremental QALYs as well.
conclusionsThere is a high probability that the TECCU Web platform is more cost-effective than standard and telephone care in the short term. Further research considering larger cohorts and longer time horizons is required.
trial registrationClinicalTrials.gov NCT02943538; https://clinicaltrials.gov/ct2/show/NCT02943538 (http://www. webcitation.org/746CRRtDN).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.